Sarepta Therapeutics, Inc. (SRPT)

Sarepta Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	2,198	1,902	1,243	933.01	701.89
Revenue Growth (YoY)	15.58%	52.97%	33.26%	32.93%	29.95%
Cost of Revenue	839.61	319.1	150.34	139.99	97.05
Gross Profit	1,359	1,583	1,093	793.02	604.84
Selling, General & Admin	491.72	557.87	481.87	451.42	282.66
Depreciation & Amortization Expenses	2.62	2.41	1.56	0.71	0.71
Research & Development	1,522	804.52	877.39	877.09	771.18
Other Operating Expenses	42.01	-	-	-	10
Total Operating Expenses	2,058	1,365	1,361	1,329	1,065
Operating Income	-699.78	218.08	-267.82	-536.2	-459.71
Total Non-Operating Income (Expense)	-2.44	42.69	-252.27	-153.76	40.76
Pretax Income	-702.23	260.77	-520.1	-689.96	-418.95
Provision for Income Taxes	11.19	25.54	15.88	13.53	-0.17
Net Income	-713.41	235.24	-535.98	-703.49	-418.78
Net Income to Common	-713.41	235.24	-535.98	-703.49	-418.78
Shares Outstanding (Basic)	100	95	92	88	81
Shares Outstanding (Diluted)	100	108	92	88	81
Shares Change (YoY)	-7.19%	16.75%	5.53%	7.75%	4.24%
EPS (Basic)	-7.13	2.47	-5.80	-8.03	-5.15
EPS (Diluted)	-7.13	2.34	-5.80	-8.03	-5.15
Shares Outstanding	104.96	96.9	93.73	87.95	87.13
Free Cash Flow	-307.45	-342.74	-577.1	-356.17	-481.66
Free Cash Flow Per Share	-3.07	-3.18	-6.25	-4.07	-5.93
Gross Margin	61.81%	83.22%	87.91%	85.00%	86.17%
Operating Margin	-31.83%	11.47%	-21.54%	-57.47%	-65.50%
Profit Margin	-32.45%	12.37%	-43.11%	-75.40%	-59.66%
FCF Margin	-13.99%	-18.02%	-46.42%	-38.17%	-68.62%
EBITDA	-655.26	235.37	-250.78	-494.34	-421.69
EBITDA Margin	-29.81%	12.38%	-20.17%	-52.98%	-60.08%
EBIT	-699.78	218.08	-267.82	-536.2	-459.71
EBIT Margin	-31.83%	11.47%	-21.54%	-57.47%	-65.50%
Effective Tax Rate	-1.59%	9.79%	-3.05%	-1.96%	0.04%

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q